No Data
No Data
Express News | VYNE Therapeutics Announces Composition Of Matter Patent For Its VYN202 BD2-Selective BET Inhibitor
Express News | Vyne Therapeutics Inc - Granted Patent Covers Compound in Vyne's Vyn202 Program and Has a 20-Year Term That Will Expire in June 2042
Express News | Vyne Therapeutics Announces Granting of Composition of Matter Patent for Vyn202, a Novel BD2-Selective Bet Inhibitor
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
Express News | Vyne Therapeutics Announces Appointment of Subhashis Banerjee, M.d. as Senior Vice President of Clinical Development
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
No Data
1522357560466 : what are the levels you are looking at sir?
TrytosaveabitOP 1522357560466: Haven’t set any just yet
1522357560466 : keen for the update, thanks